JKJimmy Kizza

Jimmy Kizza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jimmy Kizza has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Low Birthweight and Prematurity, but not Malaria Chemoprevention, Are Associated With Reduced Pneumococcal Vaccine Immunogenicity in Ugandan Infants

    by Kenneth Musinguzi, Alyssa N Sbarra, Florian Bach, Felistas Nankya, Karen Bino Achom, Caroline Mwubaha, Patience Nayebare, Evelyn Nansubuga, Abel Kakuru, Jimmy Kizza, et al.

    Background: Malaria exposure has been hypothesized to alter immune responses to childhood vaccines, but evidence is inconsistent. We evaluated whether early-life malaria exposure and perennial malaria chemoprevention (PMC) modify antibody responses to the 10-valent pneumococcal conjugate vaccine (PCV-10) among infants in a high malaria transmission setting in eastern Uganda. Methods: This study was nested within the MIC-DroP trial (NCT04978272) whereby 202 infants were selected for inclusion. Serotype-specific IgG concentrations were measured using an in-house multiplex seroassay from samples obtained at 8 and 24 weeks of age. Immunogenicity was quantified as the log10 fold-change in IgG concentration between the 8- and 24-week timepoints, and seroconversion as ≥0.35 μg/mL at week 24 (ie, seropositive). Generalized estimating equation models were used to assess associations of PCV-10 immunogenicity and seroconversion with malaria exposure, malaria chemoprevention, and birth outcomes. Results: Among the 195 of 202 infants who completed the three-dose PCV-10 series, neither infant PMC nor malaria exposure from study enrollment to 14 weeks were associated with PCV-10 immunogenicity or seroconversion. In contrast, low birthweight (<2500 g) was associated with lower immunogenicity (82% lower [95% confidence interval (CI): 43–94%] antibody fold-change, P = .003) and reduced odds of seroconversion (OR = 0.19 [95% CI: 0.06–0.57], P = .003); preterm birth (<37 weeks) showed similar associations (79% lower [95% CI: 24–94%] antibody fold-change, P = .018; OR = 0.181 [95% CI: 0.05–0.65], P = .009). Conclusions: In this malaria-endemic setting, early-life malaria exposure and chemoprevention did not measurably alter PCV-10 antibody responses. However, low birthweight and prematurity were associated with reduced vaccine immunogenicity.

  • Open Access

    The Value of Ultrasound in Improving Gestational Age Estimates and Impact on Accuracy of Maternal-Child Health Metrics in Rural Uganda

    by Jimmy Kizza, Anju Ranjit, Kavya Subramaniam, Tonny Rachkara, Miriam Aguti, James B. Wire, Miriam Nakalembe, Timothy Ssemukuye, Michelle E. Roh, Tamara D. Clark, et al.

    Background: In resource-limited settings, pregnancy dating often relies on the last menstrual period (LMP). Gestational age (GA) is best confirmed by ultrasound. The value of ultrasound for improving population-level maternal health indicators remains understudied.Methods: This was a cohort study of 2,757 pregnant women enrolled in a trial comparing intermittent preventative treatments for malaria. Ultrasound was performed between 12–20 weeks gestation to confirm GA. Final estimated due date (F-EDD) was determined using established standards to assess discordance between LMP-based (LMP-EDD) and ultrasound-based (US-EDD) EDD. We compared LMP-EDD with F-EDD for estimating preterm birth (PTB) and small for gestational age (SGA) prevalence.Results: Among 2,757 participants, 1,566 (56 8%) had unknown LMP and were dated by ultrasound. Among 1,191 with known LMP, 253 (21 2%) were redated by ultrasound, of whom 229 had live births. PTB prevalence was higher using LMP-EDD than F-EDD (7 3% vs 5 2%, p=<0 001). SGA prevalence did not differ significantly (22% vs. 23 1%, p=0.05). Among participants with LMP-EDD redated by ultrasound, prevalence of PTB was overestimated nearly fourfold by LMP compared to ultrasound (13 1% vs. 3 5%, p=<0 001); SGA rates were similar (17 9% vs. 23 1%, p=0 05).Interpretation: Reliance on LMP-EDD overestimated PTB prevalence, underscoring the value of ultrasound for accurate maternal health surveillance.

  • Open Access

    Low birthweight and prematurity, but not malaria chemoprevention, are associated with reduced pneumococcal vaccine immunogenicity in Ugandan infants

    by Kenneth Musinguzi, Alyssa N Sbarra, Florian Bach, Felistas Nankya, Karen Bino Achom, Caroline Mwubaha, Patience Nayebare, Evelyn Nansubuga, Abel Kakuru, Jimmy Kizza, et al.

    Background: Malaria exposure has been hypothesized to alter immune responses to childhood vaccines, but evidence is inconsistent. We evaluated whether early-life malaria exposure and perennial malaria chemoprevention (PMC) modify antibody responses to the 10-valent pneumococcal conjugate vaccine (PCV-10) among infants in a high malaria transmission setting in eastern Uganda. Methods: This study was nested within the MIC-DroP trial ( NCT04978272 ) whereby 202 infants were selected for inclusion. Serotype-specific IgG concentrations were measured using an in-house multiplex seroassay from samples obtained at 8 and 24 weeks of age. Immunogenicity was quantified as the log 10 fold-change in IgG concentration between the 8 and 24-week timepoints, and seroconversion as ≥0.35 μg/mL at week 24 (i.e., seropositive). Generalized estimating equation models were used to assess associations of PCV-10 immunogenicity and seroconversion with malaria exposure, malaria chemoprevention and birth outcomes. Results: Among the 195 of 202 infants who completed the three-dose PCV-10 series, neither infant PMC nor malaria exposure from study enrollment to 14 weeks were associated with PCV-10 immunogenicity or seroconversion. In contrast, low birthweight (<2500g) was associated with lower immunogenicity (82% lower antibody fold-change, p=0.003) and reduced odds of seroconversion (OR=0.19, p=0.003); preterm birth (<37 weeks) showed similar associations (79% lower antibody fold-change, p=0.018; OR=0.181, p=0.009). Conclusion: In this malaria-endemic setting, early-life malaria exposure and chemoprevention did not measurably alter PCV-10 antibody responses. However, low birthweight and prematurity were associated with reduced vaccine immunogenicity.


  • Open Access

    Natural History and the Burden of Malaria During the First Year of Life in the High-Transmission Setting of Uganda

    by Miriam Aguti, Joaniter I. Nankabirwa, Jimmy Kizza, Abel Kakuru, Timothy Ssemukuye, Harriet Adrama, Peter Olwoch, Bishop Opira, Baker Odongo, Kylie Camanag, et al.

    : Infants under 1 year of age are considered partially protected from malaria because of maternal antibodies and fetal hemoglobin. However, emerging evidence suggests that the malaria burden in this age group may be underestimated. A cohort of 855 infants in Busia District, Uganda, was enrolled in the present study to characterize malaria incidence and parasite prevalence during the first year of life and to identify risk factors for these outcomes. The study was conducted from 2021 to 2025, before the malaria vaccine roll-out. Infants born to HIV-uninfected women were enrolled at 4–8 weeks of age and followed by active and passive case detection to 1 year of age in a dedicated study clinic that is open 7 days/week. Routine visits every 4 weeks included assessments for parasitemia via microscopy and quantitative polymerase chain reaction testing. Over 706.7 person-years of follow-up, 662 malaria episodes occurred. The overall prevalence of microscopic parasitemia was 7.9%, and the combined prevalence of microscopic and submicroscopic parasitemia was 21.8%. Sickle cell trait (Hemoglobin AS) conferred 39% protection against symptomatic malaria but was not associated with the risk of parasitemia. Modern housing construction and higher maternal education were independently associated with reduced malaria risk. District-wide distribution of long-lasting insecticide-treated nets containing alpha–cypermethrin plus chlorfenapyr in October 2023 was followed by an 80% reduction in malaria incidence and significant declines in parasitemia prevalence. These findings underscore the urgent need for age-appropriate preventative interventions targeting young infants, such as earlier vaccine administration or treatment with monoclonal antibodies, alongside sustained investment in next-generation vector control and attention to socioeconomic determinants of malaria risk.


  • Recurrent Plasmodium falciparum Parasitemia and Drug Resistance Mutations During Intermittent Preventive Treatment of Malaria in Pregnancy in Uganda

    by Jimmy Kizza, Thomas Katairo, Abel Kakuru, Bienvenu Nsengimaana, Trevor Esilu, Innocent Wiringilimaana, Francis D Semakuba, Inna Gerlovina, Nicholas Hathaway, Jessica Briggs, et al.

    Background: Intermittent preventive treatment with monthly sulfadoxine-pyrimethamine (IPTp-SP) is recommended during pregnancy in malaria-endemic countries. However, widespread resistance of Plasmodium falciparum to SP has compromised its efficacy, and the alternative dihydroartemisinin-piperaquine (DP) is under study. Potential selection of drug resistance is important. Methods: We sequenced 1377 samples collected from pregnant women enrolled in a trial comparing monthly SP, DP, and DP + SP for IPTp in Busia, Uganda and with asymptomatic parasitemia at the time of IPTp administration. We characterized known markers of drug resistance and assessed the 28-day cumulative risk of recurrent parasitemia, with genotyping to distinguish recrudescence from new infections. Results: Among 771 samples collected on the day IPTp was initiated, the prevalences of 5 resistance mutations in P. falciparum dihydrofolate reductase (PfDHFR) and dihydropteroate synthase (PfDHPS) were nearly 100%, and the PfDHFR I164L and PfDHPS A581G mutations, associated with high-level resistance, had combined prevalence of 26.5%. The cumulative risks of recurrent parasitemia (SP 57.8%, DP 4.1%, DP + SP 3.9%), symptomatic malaria (SP 9.3%, DP 1.1%, DP + SP 0.3%), and recrudescent parasitemia (SP 40.1%, DP 2.0%, DP + SP 0.8%) were all significantly greater in the SP arm, with risks greatest in primigravidae. In the IPT-SP arm, the combined prevalence of the PfDHFR I164L and PfDHPS A581G mutations increased significantly from 24.9% at initiation of IPTp to 35.2% after receipt of IPTp-SP. Infection with mutant parasites was associated with non-significant increases in risks of recrudescence. Conclusions: Intermittent preventive treatment with monthly sulfadoxine-pyrimethamine had poor antimalarial preventive efficacy and selected for increased drug resistance, questioning the value of this intervention.


  • Open Access

    Caregivers’ understanding of sickle cell disease: Knowledge, attitudes, and practices at Masafu general hospital, Uganda. A survey

    by Walter Tevin Kiirya, Jimmy Kizza, Innocent Ayesiga

    Background Sickle cell disease (SCD) is a genetic blood disorder that affects approximately 20 million people worldwide, with a relatively high prevalence in sub-Saharan Africa (SSA). Caregivers’ understanding of SCD is crucial to managing this condition. They can be potential stewards of increasing SCD awareness in communities if they are equipped with the correct information. Therefore, the study examined knowledge, attitudes, and practices regarding SCD among caregivers of children receiving chronic care at Masafu General Hospital. Methods One hundred caregivers were recruited for a cross-sectional survey. The survey used interviewer-administered questionnaires to collect the data. This was then entered into Epidata Manager Version 4.6.0.6 and exported to STATA version 17.0 for analysis. Results Among 100 sampled people, 80% were female. Most (98%) had heard of SCD, mainly from health facilities (86%). Nearly half (43%) didn’t know that both parents with SCD don’t guarantee a normal child, and 15% of caregivers were unaware of SCD’s cause. A large majority (93%) hadn’t tested their haemoglobin, and 95% didn’t know their partners’ status. Twenty-two per cent believed SCD prevents normal work, perceiving sufferers as weak. Conclusion The study results indicate the need for continuous caregiver education and increased SCD awareness campaigns in Uganda communities, with strategies to encourage more male involvement.

  • Open Access

    Recurrent Plasmodium falciparum parasitemia and drug resistance mutations during intermittent preventive treatment of malaria in pregnancy in Uganda

    by Jimmy Kizza, Thomas Katairo, Abel Kakuru, Bienvenu Nsengimaana, Trevor Esilu, Innocent Wiringilimaana, Francis D Semakuba, Inna Gerlovina, Nicholas Hathaway, Jessica Briggs, et al.

    Background: Intermittent preventive treatment with monthly sulfadoxine-pyrimethamine (IPTp-SP) is recommended during pregnancy in malaria-endemic countries. However, widespread resistance of Plasmodium falciparum to SP has compromised its efficacy, and the alternative dihydroartemisinin-piperaquine (DP) is under study. Potential selection of drug resistance is of interest. Methods: We sequenced 1377 samples collected from pregnant women enrolled in a trial comparing monthly SP, DP, and DP+SP for IPTp in Busia, Uganda and with asymptomatic parasitemia at the time of IPTp administration. We characterized known markers of drug resistance and assessed the 28-day cumulative risk of recurrent parasitemia, with genotyping to distinguish recrudescence from new infections. Results: Among 771 samples collected on the day IPTp was initiated, the prevalences of five resistance mutations in P. falciparum dihydrofolate reductase (PfDHFR) and dihydropteroate synthase (PfDHPS) were nearly 100%, and the PfDHFR I164L and PfDHPS A581G mutations, associated with high-level resistance, had combined prevalence of 26.5%. The cumulative risks of recurrent parasitemia (SP 57.8%, DP 4.1%, DP+SP 3.9%), symptomatic malaria (SP 9.3%, DP 1.1%, DP+SP 0.3%), and recrudescent parasitemia (SP 40.1%, DP 2.0%, DP+SP 0.8%) were all significantly greater in the SP arm, with risks greatest in primigravidae. In the IPT-SP arm, the combined prevalence of the PfDHFR I164L and PfDHPS A581G mutations increased significantly from 24.9% at initiation of IPTp to 35.2% after receipt of IPTp-SP. Infection with mutant parasites was associated with non-significant increases in risks of recrudescence. Conclusions: IPTp-SP had poor preventive efficacy and selected for increased drug resistance, questioning the value of this intervention.


  • Open Access

    Dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine versus either drug alone for intermittent preventive treatment of malaria in pregnancy: A double-blind, randomized, controlled phase 3 trial from Uganda

    by Abel Kakuru, Jimmy Kizza, Miriam Aguti, Harriet Adrama, John Ategeka, Peter Olwoch, Miriam Nakalembe, Joaniter I. Nankabirwa, Bishop Opira, Nida Ozarslan, et al.

    Background: To mitigate adverse consequences of malaria in pregnancy, the World Health Organization recommends intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine–pyrimethamine. However, the effectiveness of IPTp with sulfadoxine–pyrimethamine has been threatened by widespread Plasmodium falciparum resistance, especially in East and Southern Africa. For IPTp, dihydroartemisinin–piperaquine has shown superior antimalarial effects compared to sulfadoxine–pyrimethamine, but sulfadoxine–pyrimethamine has been associated with improved birth outcomes compared to dihydroartemisinin–piperaquine. We hypothesized that a combination of both dihydroartemisinin–piperaquine and sulfadoxine–pyrimethamine would provide superior birth outcomes compared to either drug alone. Methods and findings: We conducted a double-blinded, randomized, controlled trial of 2,757 pregnant women in Uganda, where resistance of malaria parasites to sulfadoxine–pyrimethamine is widespread. Women were randomly assigned (1:1:1) to monthly IPTp with sulfadoxine–pyrimethamine, dihydroartemisinin–piperaquine, or dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine. The primary outcome was the risk of a composite adverse birth outcome defined as any of the following: spontaneous abortion, stillbirth, low birthweight (LBW, < 2,500 g), preterm delivery (p = 0.70) or sulfadoxine–pyrimethamine (30.0% versus 26.4%, RR 1.14 [95% CI 0.98–1.33]; p = 0.10). The risk of a composite adverse birth outcome was higher with dihydroartemisinin–piperaquine compared to sulfadoxine–pyrimethamine (30.9% versus 26.4%, RR 1.17 [95% CI 1.01–1.36]; p = 0.04). Considering individual adverse birth outcomes, combining dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine was associated with a higher risk of small-for-gestational age (23.4% versus 18.7%, RR 1.25 [95% CI 1.04–1.51]; p = 0.02) and low birthweight (8.6% versus 5.8%, RR 1.48 [95 CI 1.04–2.12]; p = 0.03) compared to sulfadoxine–pyrimethamine and a higher risk of preterm delivery (5.3% versus 3.1%, RR 1.73 [95% CI 1.07–2.79]; p = 0.03) compared to dihydroartemisinin–piperaquine. During pregnancy, compared to sulfadoxine–pyrimethamine, dihydroartemisinin–piperaquine was associated with a 94% reduction in the incidence of symptomatic malaria (0.46 versus 0.03 episodes per person-year, incidence rate ratio 0.06 [95% CI 0.03–0.12]; p < 0.001) and a 97% reduction in the risk of microscopic parasitemia (17.7% versus 0.6%, RR 0.03 [95% CI 0.02–0.05]; p < 0.001), but dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine was not associated with improved malaria outcomes over dihydroartemisinin–piperaquine alone. There were no significant differences in the incidence of any grade 3–4 adverse events between the treatment arms. As this study was conducted in an area of high transmission intensity with widespread resistance to sulfadoxine–pyrimethamine, findings may not be generalizable to other settings. Conclusions: Despite the superior antimalarial activity of dihydroartemisinin–piperaquine, sulfadoxine–pyrimethamine alone was associated with improved birth outcomes. Combining dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine for IPTp did not improve birth outcomes compared to either sulfadoxine–pyrimethamine or dihydroartemisinin–piperaquine alone. Trial registration: ClinicalTrials.gov (NCT04336189; https://clinicaltrials.gov/study/NCT04336189).


  • Open Access

    Gestational SARS-CoV-2 Infection in a Ugandan Birth Cohort: High Incidence, Mild Maternal Disease, and Evidence of Association with Transient Infant Stunting

    by Karen B. Jacobson, Katharina Röltgen, Brandon Lam, Patience Nayebare, Abel Kakuru, Jimmy Kizza, Miriam Aguti, Felistas Nankya, Jessica Briggs, Saki Takahashi, et al.

    : Many questions remain about the prevalence and effects of SARS-CoV-2 infection in malaria-endemic African countries like Uganda, particularly in vulnerable groups such as pregnant women. We describe SARS-CoV-2 immunoglobulin (Ig)G and IgM antibody responses and clinical outcomes in mother-infant dyads enrolled in malaria chemoprevention trials in Uganda. From December 2020–February 2022, among 400 unvaccinated pregnant women enrolled at 12–20 weeks gestation and followed through delivery, 128 (32%) were seronegative for anti-SARS-CoV-2 IgG and IgM at enrollment and delivery, 80 (20%) were infected prior to or early in pregnancy, and 192 (48%) were infected or re-infected with SARS-CoV-2 during pregnancy. We observed preferential binding of plasma IgG to Wuhan-Hu-1-like antigens in individuals seroconverting up to early 2021, and to Delta variant antigens in a subset of individuals in mid-2021. Breadth of IgG binding to all variants improved over time, consistent with affinity maturation of the antibody response in the cohort. No women experienced severe respiratory illness during the study. SARS-CoV-2 infection in early pregnancy was associated with lower median length-for-age Z-score at age 3 months compared with no infection or late pregnancy infect (−1.54 versus −0.37 and −0.51, P = 0.009). These findings suggest that pregnant Ugandan women experienced high levels of SARS-CoV-2 infection without severe respiratory illness. Variant-specific serology testing demonstrated evidence of antibody affinity maturation at the population level. Early gestational SARS-CoV-2 infection was associated with transient shorter stature in early infancy. Further research should explore the significance of this finding and define targeted measures to prevent infection in pregnancy.


  • Drug–Drug Interaction Between Dihydroartemisinin–Piperaquine and Sulfadoxine‐Pyrimethamine During Malaria Chemoprevention in Pregnant Women

    by Norah Mwebaza, Michelle E. Roh, Yourong Z. Geng, Leonard Opio, Bishop Opira, Florence Marzan, Moses W. Mwima, Timothy Ssemukuye, Kevin Guo, David Gingrich, et al.

    Co‐administration of dihydroartemisinin–piperaquine (DP) and sulfadoxine‐pyrimethamine (SP) for intermittent preventive treatment of malaria in pregnancy (IPTp) may be superior in preventing adverse birth outcomes compared with either therapy alone, but potential drug–drug interactions require investigation. We conducted intensive and sparse pharmacokinetic (PK) studies in a subset of Ugandan women participating in a randomized controlled trial of monthly IPTp with SP vs. DP vs. DP + SP. Intensive PK sampling was performed from day 0 to 23 after dosing at 28 weeks gestation in 87 participants across treatment arms. Sparse sampling was performed on day 28 (trough) after dosing at 20 and 28 gestational weeks in additional 196 participants receiving SP vs. DP + SP. Intensive PK analysis demonstrated that compared with SP alone, co‐administration of DP + SP was associated with lower maximal concentrations, the area under the concentration–time curves (AUC), and day 23 concentrations of sulfadoxine (25%, 25%, and 27%) and pyrimethamine (26%, 34%, and 32%) (P < 0.05 for all comparisons). Sparse PK results demonstrated participants co‐administered DP + SP had lower trough concentrations after dosing at 20 and 28 gestational weeks for sulfadoxine (6%, P = 0.68 and 31%, P = 0.023, respectively) and pyrimethamine (18%, P = 0.032 and 33%, P < 0.001, respectively) compared with SP alone. Co‐administration of DP + SP was associated with a 19% reduction in piperaquine AUC (P = 0.046), but no significant difference in other PK parameters compared with DP alone. In summary, co‐administration of DP + SP was associated with significantly reduced SP exposure, with a greater magnitude during the third vs. second trimester. The clinical consequences of this interaction are yet unknown.